PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
3986.96%
Revenue growth of 3986.96% vs. zero growth in Biotechnology. Walter Schloss might still want to see if it can translate into profits.
804.39%
Gross profit growth of 804.39% while Biotechnology median is zero. Walter Schloss might see a slight advantage that could be built upon.
35.83%
Positive EBIT growth while Biotechnology median is negative. Peter Lynch might see a strong competitive advantage in operations.
35.83%
Operating income growth of 35.83% while Biotechnology median is zero. Walter Schloss might see a modest advantage that can expand.
36.40%
Positive net income growth while Biotechnology median is negative. Peter Lynch would view this as a notable competitive advantage.
37.84%
EPS growth of 37.84% while Biotechnology median is zero. Walter Schloss might see a slight edge that could compound over time.
37.84%
Diluted EPS growth of 37.84% while Biotechnology median is zero. Walter Schloss might see a slight edge that could improve over time.
2.81%
Share growth above Biotechnology median by more than 2x. Jim Chanos would suspect over-dilution or repeated equity raises.
2.81%
Diluted share growth above 2x Biotechnology median. Jim Chanos would suspect undue issuance or heavy employee stock compensation.
No Data
No Data available this quarter, please select a different quarter.
-14.43%
Negative OCF growth while Biotechnology median is -9.28%. Seth Klarman would ask if accounting or macro issues hamper the firm specifically.
-14.57%
Negative FCF growth while Biotechnology median is -8.09%. Seth Klarman would see if others in the industry are still generating positive expansions in free cash.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-1885.22%
Negative 10Y OCF/share CAGR while Biotechnology median is 0.00%. Seth Klarman would suspect the firm is failing to keep pace with industry peers.
90.95%
OCF/share CAGR of 90.95% while Biotechnology median is zero. Walter Schloss might see a slight advantage that can compound if momentum builds.
81.42%
3Y OCF/share growth of 81.42% while Biotechnology median is zero. Walter Schloss might see a modest advantage that could compound if momentum holds.
-991.23%
Negative 10Y net income/share CAGR vs. Biotechnology median of 0.00%. Seth Klarman might see a fundamental problem if peers maintain growth.
94.68%
Net income/share CAGR of 94.68% while Biotechnology median is zero. Walter Schloss might see a modest advantage that can expand mid-term.
84.15%
3Y net income/share CAGR of 84.15% while Biotechnology median is zero. Walter Schloss might see a small advantage that can be scaled further.
1611.09%
Equity/share CAGR exceeding 1.5x Biotechnology median of 7.85% over 10 years. Joel Greenblatt would see if a high ROE underlies this compounding advantage.
-55.02%
Negative 5Y equity/share growth while Biotechnology median is 0.00%. Seth Klarman suspects firm-specific weaknesses if peers grow equity mid-term.
127.30%
3Y equity/share CAGR of 127.30% while Biotechnology median is zero. Walter Schloss sees a modest short-term advantage that could compound if momentum persists.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-7.25%
Assets shrink while Biotechnology median grows. Seth Klarman might see a strategic refocus or potential missed expansion if demand is present.
-8.96%
Negative BV/share change while Biotechnology median is -10.20%. Seth Klarman sees a firm-specific weakness if peers accumulate net worth.
-36.45%
Debt is shrinking while Biotechnology median is rising. Seth Klarman might see an advantage if growth remains possible.
-19.33%
R&D dropping while Biotechnology median is rising. Seth Klarman wonders if we risk ceding future innovation or if peers overspend.
-34.65%
SG&A decline while Biotechnology grows. Seth Klarman sees potential cost advantage or a risk if it hurts future growth.